IMHO, if you have serum D3 levels in the neighbourhood of 100 nmol/L or lower, you need to look elsewhere for the source of a calcium imbalance.
IMHO, the calcium being high *in relation to cellular magnesium* is the key point. i also note with interest mention of low dietary protein and increased need for things like vitamin E.. FYI supplemental magnesium and vitamin E, along with high dietary protein intake, are all components of the 40 year old klenner protocol for MS.
i think the folks that are saying high calcium high calcium need to adjust the thinking to low magnesium, low magnesium.
in the research, a 'healthy control' minimum for serum magnesium would be 0.91 mmol/L. ms patients do tend to be low in magnesium.
on magnesium in MS patients and healthy controls:
http://www.sid.ir/en/VEWSSID/J_pdf/118620080207.pdf
MS Patient 1.87 ± 0.37
Healthy 2.22 ± 0.24
these researchers give the units for mag as 'mg' which is next door to useless unless we start making assumptions and doing some guesswork:
conversion factor
mg/dL 0.411 mmol/L
for starters 2.22 mg can't be per dL, that's way too low. so let's say they are using mg/L and we convert it to mg/dL giving us a mean of 222 in healthy controls. 222*.411 = 91.2 mmol/L. that's actually remarkable considering the different abstract i previously posted, which says everyone should supplement magnesium if the serum level drops below 0.90 mmol/L.
comparing the MS level.. 1.87 -> 187*.411 = 76.8 mmol/L.
normal range is typically given as 0.70-1.10. look at that, the ms patients in the above study have 'normal magnesium'. clearly not good enough! if you're hearing 'magnesium is normal' you might want to take a closer look.
nice little treatment article:
http://www.ncbi.nlm.nih.gov/pubmed/11136367
The effect of magnesium oral therapy on spasticity in a patient with multiple sclerosis.
The effects of magnesium glycerophosphate oral therapy on spasticity was studied in a 35-year-old woman with severe spastic paraplegia resulting from multiple sclerosis (MS). We found a significant improvement in the spasticity after only 1 week from the onset of the treatment on the modified Ashworth scale, an improvement in the range of motion and in the measures of angles at resting position in lower limbs. No side-effects were reported and there was no weakness in the arms during the treatment.